Skip to NavigationSkip to content

Johnson & Johnson

J&J’s longest-standing CFO finally steps down

Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from his position in September of this year.

Caruso spent close to 12 years in his position as CFO of the pharma giant and was the longest serving in this position during the company’s 132-year history.

FDA expands J&J Zytiga combo's indication to include castration-sensitive prostate cancer

Johnson & Johnson has announced that Zytiga (abiraterone acetate) in combination with prednisone has been awarded FDA approval in the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC).

Theravance seals potential $1bn deal with J&J

The JAK inhibitor field is beginning to heat up – AbbVie is soon to enter Phase 3 with its predicted best-in-class therapy, Gilead is working with Galapagos on a potential rival and Celgene started the year off with a $1.1 billion upfront deal for Impact Biomedicine, gaining them access to its JAK2 inhibitor.

J&J's apalutamide shows strength in non-metastatic prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide significantly improved median metastasis-free survival (MFS) by two years compared to placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

US court upholds ruling that J&J's Remicade patent is invalid

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis drug Remicade (infliximab) is invalid, upholding a previous decision by the US Patent and Trademark Office (PTO) that the antibodies covered by the patent were already disclosed in an earlier patent.

J&J withdraws controversial vaginal mesh from Australian market

Johnson & Johnson has withdrawn its controversial vaginal mesh product from the Australian market after missing a deadline requiring all such products to carry warnings of potential side-effects. The move follows legal action from more than 700 Australian women who were left in constant pain after having the mesh implanted.

Top Ten most popular articles on Pharmafile.com this week

The Xmas break is now a distant memory as we move further into January, and with another Friday comes another rundown of the top ten most popular news stories with Pharmafile.com readers this week.

Among the top stories this week was the news that Shire is to split its business into two distinct units, Nestle could be the frontrunner in the competition to acquire Merck KGaA's consumer health unit, and a remarkable once-weekly, slow-release HIV pill has been developed.

Bayer and J&J successfully reverse $28 million Xarelto court payout

Bayer and Johnson & Johnson have managed to avert a payout of $27.8 million after a Pennsylvania state court judge overturned the award to a couple accusing the pair of firms of failing to adequately warn patients of the internal bleeding risks of its blood thinner drug Xarelto.

J&J’s predicted blockbuster depression posts P2 data

Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The drug is an altered form of ketamine, more commonly known as a party drug, but the chemical is now being widely studied for its therapeutic potential within mental health.

Esketamine is delivered in an intranasal formulation, alongside standard oral antidepressants. J&J has big hopes for the treatment, predicting that it will become a blockbuster treatment should it see approval.

Pharmafile.com's top ten stories of 2017

After a packed year that has flown by, we've reached the final top ten of 2017. Below you can find the biggest stories of the year that proved most popular with our readers.

It's been a year characterised by uncertainty and scandal, but eventful throughout. From J&J's massive acquisition of Actelion bringing in the year, to Teva's increasingly tragic fall from grace and the shadows cast on the industry and beyond by President Trump and Brexit, 2017 was a standout year for more than just a few reasons.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches